Product Details
Theragnostics’ clinical lead, THG-001 (68Ga-THP-PSMA), is being developed with our proprietary Galli® single-vial kit manufacturing technology to provide valuable diagnostic information on the status of patients with prostate cancer. A Phase I clinical trial of THG-001 was completed during 2016 and results of the trial have been published in the Journal of Nuclear Medicine.
The Phase II trial of THG-001 is now complete. More information about this trial can be found on clinicaltrials.gov here.
A Phase III trial is currently being registered following Theragnostics meeting with the FDA in February 2019.
Further clinical studies are currently in plan for other oncology indications to take THG-008 into Phase II.
Further updates will be added in due course.
Theragnostics’ proprietary clinical lead, THG-001 (THP-PSMA), is being developed with our Galli® technology to provide valuable diagnostic information on the status of patients with prostate cancer. A Phase I clinical trial of THG-001 was completed during 2016 and results of the trial have been published in the Journal of Nuclear Medicine. THG-001 is now recruiting for a Phase II clinical trial.
More information about the trial can be found on clinicaltrials.gov here.
An article on diagnosing prostate cancer and recent advances in radiopharmaceutical imaging by Theragnostics CEO, Dr Greg Mullen was featured in Diagnostic Imaging Europe in November 2017.
Partnered development program.
Partnered development program.